Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

16. Juli 2019 09:00 ET | Quelle: GeoVax, Inc.

GeoVax Announces Upcoming Presentation of Lassa Fever Vaccine Data

ATLANTA, GA, July 16, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in developing human vaccines, announced today that Senior...
11. März 2019 09:00 ET | Quelle: GeoVax, Inc.

GeoVax Provides Product Development and Corporate Update

ATLANTA, GA, March 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines and immunotherapies using its novel viral vector...
26. September 2018 09:00 ET | Quelle: GeoVax, Inc.

GeoVax Awarded $2.4 Million from U.S. Department of Defense to Advance Lassa Fever Vaccine

ATLANTA, GA, Sept. 26, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines, announced today that the U.S....
30. Mai 2018 09:00 ET | Quelle: GeoVax, Inc.

GeoVax to Present at the 2018 ASM Microbe Conference

ATLANTA, GA. , May 30, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVX), winner of the 2018 “Best Biotech” Vaccine Industry Excellence Award at the World Vaccine Congress, announced today...
19. April 2018 09:00 ET | Quelle: GeoVax, Inc.

GeoVax to Present its MVA Vector Platform Technology at Vaccinology Conference

ATLANTA, GA, April 19, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that its Chief Scientific Officer, Dr. Farshad...